Newron Pharmaceuticals to Host 2018 R&D Day on October 31 in New York City – Save the Date

Sept. 12, 2018 11:00 UTC

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that its 2018 R&D Day will be held in New York City on October 31, 2018, from 10:00AM to 1:00PM EDT.

Stefan Weber, Chief Executive Officer, Ravi Anand, CMO, and other senior members of Newron’s management team will host the event, which will focus on the Company’s clinical and commercial pipeline, regulatory updates and financial outlook.

In addition to presentations by Newron’s management team, the R&D Day will feature presentations from leading experts in the fields of schizophrenia, treatment resistant schizophrenia and Rett syndrome.

Institutional investors, analysts and media representatives interested in attending can email to register and to receive additional details. Please note that pre-registration is required to attend in person. The R&D Day will also be accessible via live webcast on Newron’s website.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit:



Stefan Weber, +39 02 6103 46 26
FTI Consulting
Julia Phillips / Natalie Garland-Collins, +44 20 3727 1000
IRF Communications
Martin Meier-Pfister, +41 43 244 81 40
MC Services
Anne Hennecke, +49 211 52925222
Paul Sagan, +1 617-374-8800, Ext. 112


Source: Newron Pharmaceuticals S.p.A.

Back to news